Acetylcholine and muscarinic agonists inhibit chemosensory activity in the rabbit carotid sinus nerve (CSN). Because the mechanism of this inhibition is poorly understood, we have investigated the kinetics and distribution of muscarinic receptors in the rabbit carotid body with the specific muscarinic antagonist [SH] Comparisons of specific binding in normal and chronic CSN-denervated carotid bodies suggest that musearinic receptors are absent on afferent terminals in the carotid body; however, nearly 50% of the specific [3H]QNB binding is lost following chronic sympathectomy, suggesting the presence of presynaptic muscarinic receptors on the sympathetic innervation supplying the carotid body vasculature. Autoradiographic studies have localized the remainder of [3H]QNB binding sites to Iobules of type I and type II parenchymal cells. In separate experiments, the muscarinic agonists, oxotremorine (100/~M) and bethanechol (100 ~tM) were shown to inhibit both the release of catecholamines and the increased CSN activity evoked by nicotine (50/~M) stimulation of the in vitro carotid body, Our data suggest that muscarinic inhibition in the rabbit carotid body is mediated by receptors located on type I cells which are able to modulate the excitatory actions of acetylcholine at nicotinic sites.
INTRODUCTION
The carotid body is an arterial chemosensory organ whose parenchyma consists of two distinct cell types in close association with a dense capillary network. Type I (glomus) cells possess abundant dense and clear cored synaptic vesicles, mitochondria and a highly conspicuous rough endoplasmic reticulum. Specialized terminals formed by afferent fibers from the carotid sinus nerve (CSN) synaptically appose the type I cells while slender cytoplasmic processes of type II cells, whose cytology resembles that of Schwann cells, envelop the afferent terminal-type I cell complex. Presumably, responses in the CSN produced by exposure of the carotid body to hypoxia, hypercapnia or low pH result from the release of a transmitter from type I cells which excites the adjacent afferent nerve terminals.
Early pharmacological studies by Eyzaguirre and his colleagues (see ref. 14 for review) of the actions of acetylcholine (ACh) in the mammalian carotid body were performed primarily in the cat, and revealed that nicotinic agonists excite the chemoreceptors and potentiate the response to the natural stimuli, hypoxia and hypercapnia (see ref. 14 for review). Later investigations with the cat carotid body demonstrated the presence of ACh ~' ~7. choline acetyltransferase 1'2's7 and acetylcholinesterase 25'26 in the specialized lobules of carotid body parenchymal (type l) cells. The afferent fibers innervating the organ, on the other hand. were shown to be nearly devoid of cholinergic activity ~6t9. Concurrent with many of these observations, the Loewi-type experiments of Eyzaguirre and his colleagues H'I2 led them to suggest that an 'ACh-like" substance was released as a sensory transmitter from the type I cells of the cat carotid body to act on the synaptically apposed afferent nerve terminals. However, since the formulation of this cholinergic hypothesis of chemotransmission, numerous studies (see ref. 14) have demonstrated the presence and release of multiple neuroactive substances from the type I cells of cat. rabbit and rat carotid bodies, including catecholamines (dopamine and norepinephrine) and neuropeptides (substance P and Met-enkephatin). The presentday concept that has thus evolved envisions some or all of these neuroactive agents acting in concert to determine the net sensory output of the organ. Amongst such possible interactions, evidence has accumulated that ACh release might be coupled to the release of catecholamines 24. Indeed, recent biochemical and autoradiographic studies have demonstrated that nicotinic (a-bungarotoxin) binding sites are present on the catecholamine-containing type I cells in the cat carotid body 6, and furthermore, that the nicotine-and hypoxia-evoked release of dopamine, and the accompanying increase in sensory discharge, are substantially reduced in the presence of 50 nM a-bungarotoxin ~'.
A unified interpretation of these data has unfortunately been confounded by the more recent findings that ACh is inhibitory to chemoreceptor activity in the rabbit carotid body 8'29, in contrast to its well-known excitatory actions in the cat. Pharmacological studies demonstrated that the chemosensory inhibition in the rabbit is mediated by muscarinic receptors ~'2~. However, the location of these receptors in the carotid body has not been examined, and consequently the mechanism of muscarinic inhibition is unknown.
In the present study, we have used the muscarinic antagonist, [3H]quinuclidinylbenzilate ([3H]QNB), to quantify and localize muscarinic receptors in the rabbit carotid body. Biochemical and autoradiographic data indicate that specific binding of [3H]QNB in rabbit carotid body, like that for ~-bungarotoxin in the cat carotid body, is localized to lobules of type I cells and is absent from the afferent terminals of the carotid sinus nerve (CSN). Companion studies utilizing cholinergic agonists and antagonists demonstrate that muscarinic receptors located on type I cells are able to inhibit both CSN discharge and the release of catecholamines from these cells evoked by nicotine.
A preliminary report of some of the autoradiographic observations was published earlier in this journal 7.
MATERIALS AND METHODS
Adult New Zealand white rabbits of both sexes were used in these experiments. In addition to normal, unoperated (control) animals, two groups of rabbits were chronically denervated 12-15 days prior to the experiments. Under pentobarbital anesthesia (40 mg/kg, i.v.) and with ascptic surgery, the CSN were resected bilaterally in one group of 7 rabbits, while in a second group of 6, the superior cervical ganglia (SCG) were removed bilaterally along with their ganglioglomerular nerves to the carotid body.
Binding assay
Methodological details of the binding experiments have been published previously 7. Briefly, carotid bodies were rapidly removed from normal or chronically dencrvated animals and dissected free of encapsulating connective tissue in ice-cold 100% O2-equilibrated, modified Tyrode's solution (in mM: NaC1, 112; KCI, 4.7; CaCI 2, 2.2; MgCI 2, 1.1; sodium glutamate, 42; HEPES, 5; pH 7.43 at 37 °C with glucose 1 mg/ml). Wet weights were determined on a Cahn electrobalance equipped with a humidified chamber to prevent drying of the tissues. The tissue samples were transferred to glass scintillation vials containing 1 ml of modified Tyrode's solution, placed in a waterbath-shakcr (100 Hz) and preincubated for 191 20 min at 37 °C in the presence or absence of competing drugs (10 -1° to 10 3 M atropine, QNB, bethanechol or nicotine). A subsequent 60-min incubation period began with the addition of 100 /A of media containing [3H]QNB (33.1 Ci/mmol; New England Nuclear). Following incubation, the tissue samples were washed in the shaker bath for 90 min in 2 ml of fresh buffer at room temperature. For determination of radioactivity, tissue samples were cornbusted in a Packard Model 306 sample oxidizer, solubilized in 15 ml of Oxifluor and counted in a Parkard Model 3385 scintillation spectrometer.
A utoradiography
The carotid bifurcation with the carotid body was quickly removed from the animal, and the vasculaturc flushed with 3 ml of ice-cold oxygenated buffer via the common carotid artery. Preincubation and incubation times were reduced to l0 and 20 min, respectively, to enhance histological preservation, and the normal wash media was replaced with phosphate buffered 1% paraformaldehyde and 1% glutaraldehyde. Tissue samples were post-fixed for 1 h in 1% OsO 4, dehydrated in a graded series of ethanols and embedded in Araldite. Semithin sections (0.5-1.0/~m) were mounted on gelatin-subbed glass slides, dipped in a 1:1 aqueous dilution of Kodak NTB-2 emulsion and stored with desiccant at 4 °C for 8 months. Autoradiographs were developed in Dektol (2.5 min at 18 °C), stained with methylene blue and photographed through a Zeiss Universal Microscope. Autoradiographic grain density over parenchymal cell lobules was determined in 2000x color photographs in which the episcopically illuminated silver grains appeared as unambiguous amber dots overlying the methylene blue-stained tissue. The photographs were number coded and evaluated in a 'double-blind' paradigm. The areas of parenchymal cell lobules were subsequently estimated by trimming and weighing the photographs, each of which included one or two cell lobules.
Release studies
The effects of muscarinic agents on the release of [3H]catecholamines and CNS discharge were determined according to previously published methods ~5. Briefly, pairs of carotid bodies were incubated for 2 h in 25/~M [3H]tyrosine (spec. act. 40-50 Ci/mmol), after which the organs were mounted in a tiny platinum wire basket suspended within a closed, temperature-and humidity-controlled chamber. The CSN from one carotid body was drawn up into an adjacent suction-type electrode. With the preparation in place, the carotid bodies were directly beneath an array of 22-gauge hypodermic needles which were connected through a peristaltic pump to reservoirs containing unlabeled modified Tyrode's solution. The solutions were preheated and gas-equilibrated in the reservoirs; final heating of the solutions to 37 °C was accomplished with a servocontrolled heating system. The temperature of the drop surrounding the carotid body was directly monitored through a second thermistor which was positioned to abut against the basket. The relative humidity in the chamber was maintained at 100% by a constant flow of gas, saturated with water vapor. Under control and stimulus conditions, the superfusates were equilibrated with 100% 0 2. The stimulus solutions contained nicotine (50/~M) either alone or in the presence of a muscarinic agonist (bethanechol or oxotremorine, 1(1-4 M), which was introduced 10 min before stimulation. The volumes of superfusate per collection period varied less than 5%. The superfusion rate in all experiments was 0.4 ml/min and was established in preliminary experiments which assessed the viability of the preparation, judged on the basis of a stable chemoreceptor response over a 5 h superfusion period.
The action potentials from the CSN nerve were led through an AC-coupled preamplifier to an oscilloscope and a magnetic tape recorder. The amplified signals were also led through a window discriminator to: (1) a frequency-to-voltage converter for final display of the spontaneous neural activity on a chart recorder; and (2) a digital counter-printer which read the total number of nerve impulses recorded during the collection period.
The superfusates were collected in vials containing a carrier so-lution consisting of 0.3 M acetic acid, 1 mM ascorbic acid, at a final pH of 3.6. 
B
• Non-Specific Binding . binding (displaceable by atropine, ! 0-6 M) remained stable during this rinse period, as might be expected from the reported high affinity of [3H]QNB for muscarinic receptor sites 4'41'42. In subsequent experiments, carotid bodies were washed for 90 min because retention of nonspecific binding was not reduced with longer rinse periods.
Separate experiments established the association time course for 150 pM [3H]QNB, where non-specific binding in the presence of 10 -6 M atropine equilibrated rapidly and remained at a stable value, accounting for less than 10% of total binding for up to 60 min. Specific binding (total binding minus non-specific binding) rose sharply during the initial 30 min and then plateaued. Subsequent equilibrium studies utilized 45 min incubation periods in order to achieve steady-state conditions with lower concentrations (<150 pM) of [3H]QNB. 
Equilibrium kinetics and pharmacology of [k~H]QNB binding

Localization of specific [~H]QNB binding sites
As mentioned earlier, the putative chemosensory tissue of the mammalian carotid body consists of lobules of type I (glomus) and type II (sustentacular) cells, together with the associated sensory nerve terminals. In addition, the organ also receives a significant sympathetic innervation from the nearby SCG. In order to distinguish muscarinic binding sites on parenchymal cells versus afferent or autonomic nerve terminals, we examined [3H]QNB binding in carotid bodies following chronic section of the CSN or removal of the SCG. Fig. 3 shows that 12-15 days following resection of the CSN, the number of [3H]QNB binding sites is unchanged from normal unoperated tissue. In contrast, after removal of the SCG and degeneration of the sympathetic terminals in the carotid body, [3H]QNB binding is reduced by 46%. These data suggest that muscarinic receptors are absent from CSN afferent fibers and terminals, but that sympathetic axons contain nearly one-half of carotid body muscarinic sites. An important question is whether the remaining [3H]QNB binding following sympathectomy is associated with the lobules of type I and type I1 parenchymal cells. The autoradiographic localization of muscarinic binding sites was examined in carotid bodies after incubation in 400 pM [3H]QNB. Fig.  4A ,B presents typical autoradiographs showing silver grain distributions over parenchymal cells in two normal carotid body Iobules. In these preparations, silver grains are clearly associated with the lobules of type I and type 11 cells. In the presence of 10 6 M atropine (Fig. 4C,  normal) , grains are sparse over the tissue.
Quantification of the grain density overlying lobules of type I and type II cells from normal, CSN-denervated and sympathectomized tissue samples confirmed the data from our binding experiments (Fig. 5) . Under all 3 conditions, tissues incubated with 10 -~' M atropine (non-specific binding) displayed uniformly low grain counts. Similarly low 'background' counts were measured over the lumen of blood vessels (3.81 x 10 -3 -+ 0.89 × 10 3 193 grains//~m2; not shown in the figure). Non-specific [3H]QNB binding in the autoradiographs was therefore minimal, which agrees with our binding data. In the absence of atropine (i.e. total binding), grain counts were significantly higher in all preparations (P < 0.005), reflecting specific [3H]QNB binding. These quantitative autoradiographic data suggest that specific binding within parenchymal cell lobules was unchanged following either chronic CSN denervation or chronic removal of the SCG (i.e. total binding was not significantly different for the 3 conditions, P > 0.10). Thus, degeneration of the afferent or sympathetic innervation to the carotid body does not alter the density of [3H]QNB binding sites within the parenchymal cell lobules.
The effects of muscarinic agents on catecholamine release and CSN discharge
The effects of oxotremorine on catecholamine release and chemoreceptor discharge of the CSN were tested using carotid bodies preloaded with [3H]CA synthesized from [3H]tyrosine (see Materials and Methods). The organs with their attached nerves were mounted in the in vitro recording chamber, and superfused with 100% 0 2-equilibrated media for 30-40 min prior to stimulation.
[3H]CA release and CSN discharge were then monitored during sequential 5 min prestimulus, stimulus and poststimulus collection periods, which together comprised a single 'stimulus cycle'. Following a 'control' nicotine- both peak and average CSN discharge during the 5 min stimulus period. In contrast to these nicotinic effects, oxotremorine did not alter basal [3H]CA release and CSN discharge. However, in the presence of oxotremorine, [3H]CA release and CSN discharge evoked by nicotine (50/~M) were significantly reduced; the response to nicotine returned to near control values after a 1 h wash with Tyrode's solution (100% O2-equilibrated ). In other experiments which evaluated drug effects only on nerve activity (Fig. 7) , the muscarinic agonist bethanechol was shown to inhibit the nicotine-evoked increase in CSN discharge (P < 0.05). The effects of bethanechol on the nicotine-evoked re- 
----3H-CA Release -- lease of [3H]CA was examined in a slightly different experimental protocol, in which carotid bodies were superfused in glass vials. The organs were stimulated with nicotine (50/~M) in the presence or absence of this muscarinic agonist. Fig. 8 shows that bethanechol (10 -4 M) inhibited the nicotine-evoked release of [3H]CA (expressed as a response ratio) by more than 60%, thus paralleling our results for the nicotine-evoked CSN activity obtained with the superfusion-recording chamber. Collectively, these data clearly demonstrate that muscarinic agonists can negatively modulate nicotinic actions in the rabbit carotid body.
DISCUSSION
In the present study, we have attempted to localize muscarinic receptors in the rabbit carotid body, and to examine their functional relationship to the physiological response of this arterial chemoreceptor organ. Our principal findings suggest that muscarinic receptors are located on the specialized type I parenchymal cells, and that they modulate the nicotine-evoked release of catecholamines from these cells.
The equilibrium binding data indicate that [3H]QNB associates with a single population of binding sites in the carotid body with a K a of 71.46 pM, which is similar to the high affinity binding of [3H]QNB to muscarinic receptors in brain 4x, sympathetic ganglion 4, ileum 42, heart 23, coronary artery 39, and adrenal medulla 31. Moreover, the order of potency of competing drugs for the [3H]QNB binding sites is consistent with the pharmacology of muscarinic receptors in these other tissues, where specific antagonists (QNB and atropine) possess a high affinity for the receptor, in contrast to the low affinity displayed by agonists such as bethanecho123"4°-42. Although we have not performed additional binding experiments using pirenzepine to define the muscarinic receptor subtype 3"9"z2"27, we have found in preliminary experiments that bethanechol reduces the increase of cAMP produced by forskolin in the carotid body, suggesting a negative coupling of muscarinic receptors to adenylate cyclase; in other structures negative coupling occurs via M e or M 3 muscarinic receptors 2°'3°.
Because chemosensory transduetion is thought to occur within the lobules of the type I and type II parenchymal cells (see ref. 14) , our experiments were designed to elucidate the location of putative muscarinic receptors associated with these lobules. Sensory fibers from the CSN contribute an important functional element to the chemoreceptor apparatus, namely the specialized terminals which form synaptic appositions with the type I cells 18"33. In our experiments, CSN-denervation did not reduce the amount of specific [3H]QNB binding in rabbit carotid bodies, and a quantitative autoradiographic analysis of binding within the parenChymal cell lobules likewise failed to reveal changes in bindmg after CSN degeneration. These findings imply that muscarinic receptors are absent from the sensory fibers and their terminals. However. because these nerve terminals represent less than 5% of the total volume of the carotid body 32. a small reduction in [3H]QNB binding associated with CSN-denervation might not have been detected in our experiments. While this remains a possibility, it is perhaps not consistent with the observed 46% reduction in [3H]QNB binding following degeneration of sympathetic fibers to the carotid body, which likely also represent a similarly small volume of tissue.
The 46% reduction of [3H]QNB binding in rabbit carotid body after removal of the SCG can be attributed to the loss of presynaptic muscarinic receptors associated with the axon terminals of postganglionic sympathetic neurons. In other sympathetically innervated tissues, the presence of presynaptic muscarinic receptors was shown in pharmacological experiments which demonstrated the ability of muscarinic agents to inhibit [3H]norepinephrine release 3~. While our biochemical experiments show a profound reduction in total organ binding following sympathectomy, our autoradiographic data from sympathectomized carotid bodies suggest that binding ~s unchanged within lobules of type I and type II cells. This observation is consistent with morphological studies which demonstrate that sympathetic axons rarely terminate within the parenchymal cell tobules of the carotid body 3(~. but instead form abundant nerve endings on the smooth muscle of the carotid body vasculatureL°'2s 3~,.
The function of muscarmic receptors in the carotid body can be inferred from our data showing that muscarinic agents inhibit the reletlsc of [3H]CA and CSN discharge evoked by nicotine Earlier studies by MontlBloch and Eyzaguirre 2~ and by Docherty and McQueen s showed that muscarmic drugs q ACh and pilocarpine) inhibit chemosensory units of the CSN. Likewise. our neurochemical and electrophysiological data clearly demonstrate that muscarinic receptors are negatively coupled to nicotinic excitation of the rabbit carotid bod3.
The mechanism of interaction of nicotinic and muscarinic receptors in the carotid body is unknown. In many other species, both nicotinic and muscarinic agents independently evoke the release of CA from the adrenal medulla. However. in bovine adrenal chromaffin cells, it has been reported that muscarinic agents inhibit CA release evoked by nicotine ~'3~. In this species, muscarinic agents activate guanylate cyclase, thus increasing the levels of cyclic GMP in medullary celts 43. Furthermore, cGMP analogs and phosphodiesterase inhibitors mimick the muscarinic effect by decreasing CA release in the nicotine. These findings suggest that muspresence of " . s carinic actions which are negatively coupled to nicotinic effects may be mediated by classical second messenger systems and may involve protein phosphorylation. Indeed, it has been established that phosphorylation of nicotinic receptors by a variety of protein kinases accelerates receptor desensitization (see ref. 34 In summary, a study of [3H]QNB binding in rabbit carotid body has revealed that the type I cells possess specific muscarinic receptors. Muscarinic receptors are also associated with the sympathetic innervation to the organ, while in contrast, they appear to be absent from the chemosensory CSN terminals. While the precise role of muscarinic receptors in the chemoreceptor response to natural stimuli is not fully understood, studies of their effects on nicotine evoked CA released and CSN discharge suggest that muscarinic receptors are able to modulate the actions of ACh at nicotinic sites in the rabbit carotid body.
